Bachem stock trades on the SIX Swiss Exchange under ticker BANB. Learn what drives the Bachem share price, how US investors can buy it, and the main risks.
Bachem stock refers to shares of Bachem Holding AG, a Swiss peptide and oligonucleotide manufacturer listed on the SIX Swiss Exchange under the ticker BANB. The Bachem share price is quoted in Swiss francs, so US investors typically buy the shares through a broker that offers international market access. Bachem is not listed on a US exchange and does not file reports with the SEC.
What Bachem Holding AG Actually Does
Bachem is a business-to-business supplier, not a drug developer. It manufactures peptides and oligonucleotides for pharmaceutical and biotech companies that use them as active ingredients in medicines or as laboratory research tools.
The company's core service is custom bachem peptide synthesis, which means building complex peptide chains at scales ranging from milligrams for early research to large commercial batches for approved drugs. That work places Bachem near the center of the global peptide supply chain.
Bachem was founded in Switzerland in 1971 and is headquartered in Bubendorf. It runs manufacturing sites in Switzerland, Germany, and the United States, and it also sells catalog peptides to research laboratories worldwide.
Where Bachem Stock Trades and How US Investors Can Buy It
Bachem Holding AG shares trade on the SIX Swiss Exchange in Zurich under the ticker BANB. The "Bachem Aktie" quote that German-speaking investors follow is the same security that English-speaking investors call Bachem stock.
US investors have a few practical routes to exposure, and each one carries trade-offs in cost, liquidity, and convenience.
| Route | How it works | What to watch |
|---|---|---|
| Direct purchase on the SIX | Buy BANB in Swiss francs through a broker with European market access | Currency conversion fees, Swiss stamp duty, and per-trade commissions |
| OTC quote in the US | Some brokers show a US over-the-counter line for Bachem | Thin volume, wide spreads, and tickers that can vary by platform |
| Fund or ETF exposure | Certain European and healthcare-focused funds hold Bachem as a position | Bachem usually makes up only a small slice of the portfolio |
Before buying, confirm how your broker handles Swiss taxes, currency conversion, and dividend withholding. A licensed financial advisor can help you judge whether a foreign stock fits your goals and risk tolerance.
What Moves the Bachem Share Price
Bachem's revenue depends on a limited number of large pharmaceutical customers and on the timing of their orders. A delayed shipment or a paused clinical program can shift quarterly results, which is one reason the stock often swings around earnings dates.
The biggest growth driver in recent years has been demand for GLP-1 and related metabolic peptides. Anyone researching bachem peptides tirzepatide will find that Bachem supplies manufacturing capacity to companies working in that space, although Bachem does not sell tirzepatide as its own product.
Capacity expansion is the other main storyline. Bachem has invested heavily in new production facilities, and those projects add costs before they add revenue. Currency matters too, because Bachem reports in Swiss francs while collecting revenue in several currencies.
Bachem Stock Fundamentals at a Glance
| Attribute | Detail |
|---|---|
| Exchange | SIX Swiss Exchange (Zurich) |
| Ticker | BANB |
| Reporting currency | Swiss franc (CHF) |
| Sector | Healthcare, contract development and manufacturing |
| Revenue model | Custom peptide and oligonucleotide manufacturing plus catalog products |
| Market cap | Large-cap by Swiss standards; the figure changes daily with the share price |
| Dividend | Annual payout set by the board, typically proposed at the general meeting |
Market cap is one of the most searched Bachem data points, but it moves constantly, so always check a live quote rather than a cached figure.
Key Risks to Weigh
- Valuation: Bachem has often traded at a premium earnings multiple because investors expect long-term peptide growth.
- Customer concentration: A handful of buyers account for a large share of revenue, so losing one matters.
- Capital spending: New plants are expensive, and returns arrive years after the spending starts.
- Competition: Other peptide manufacturers and large contract manufacturing organizations compete for the same contracts.
- Currency: A strong Swiss franc can pressure reported results.
None of these risks makes Bachem unusual for a specialized supplier, but together they explain why the Bachem share price can be volatile. Bachem stock is not a low-risk, income-oriented holding.
Bachem Peptides, BPC-157, and Other Search Confusions
Not every search that mentions Bachem is about investing. Queries for bachem peptides bpc-157 usually point to research-grade vendors that sell laboratory chemicals, and those sellers are separate from the publicly traded manufacturer.
The same confusion applies to tools: a bachem peptide calculator is a laboratory aid for molecular weight and dosing math in research settings, not investment information. BPC-157 is not FDA-approved for human use in the United States, and research peptides sold online are not regulated as medicines.
Bachem Holding AG is a contract manufacturer that supplies pharmaceutical companies. It is not an online store where consumers buy peptides for personal use.
How to Research Bachem Stock Before You Invest
Start with the annual and half-year reports published on the Bachem investor relations page. Following bachem ceo commentary on quarterly calls is one of the fastest ways to understand how management views order flow, pricing, and capacity.
Hiring and construction activity can also be informative. The bachem careers page and site announcements often hint at how quickly new capacity is coming online, which matters for a manufacturer that scales with headcount.
Compare Bachem with peptide peers and larger contract manufacturers before forming a view. Many investors first encounter bachem holdings stock in a broader discussion about peptide supply chains, then dig into the company's financials from there.
Frequently Asked Questions
What stock exchange is Bachem listed on?
Bachem Holding AG trades on the SIX Swiss Exchange in Zurich under the ticker BANB. The shares are quoted in Swiss francs, and the company reports its financial results in Swiss francs as well. Bachem is not listed on the NYSE or Nasdaq.
Can US investors buy Bachem stock?
Yes. US investors typically buy Bachem shares through a brokerage that offers international trading on the SIX Swiss Exchange, or through an over-the-counter quote if their platform provides one. OTC trading can involve thin volume and wide spreads, so compare total costs including currency conversion before trading.
Does Bachem pay a dividend?
Bachem has paid an annual dividend in recent years, with the amount proposed by the board and approved by shareholders at the general meeting. Because the payout is set in Swiss francs, US investors also face currency conversion and any applicable withholding when receiving it.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.